新的抗艾滋病药物——趋化因子受体拮抗剂的研究进展

目前,在艾滋病研究领域中对趋化因子及其受体的研究受到极大关注。而趋化因子受体可作为HIV-1进入T细胞的协同受体这一重大发现,为人类寻找新的抗HIV/AIDS药物提供了新的思路,即以趋化因子受体为靶点,筛选能够与该受体结合并随即阻碍HIV-1进入细胞的药物。目前针对HIV/AIDS治疗而开发的几类趋化因子受体拮抗剂都还处于临床试验阶段。本文将对趋化因子受体及趋化因子受体结抗剂的研究进展进行扼要综述。

Research Progress in New Chemokine Receptor Antagonists

In resent years, the studies in chemokines and chemokine receptors have drawn a great attention of AIDS research scientists. The findings that HIV-1 uses chemokine receptor as a co-receptor to enter T cells unfold to research scientists an entirely new pathway of searching for anti-HIV/AIDS drugs. Thus, the new drugs can bind to chemokine receptors and as a result hinder HIV-1 from entering cells. Several kinds of newly developed chemokine receptor antagonists are currently in the process of clinical trials. In this review, the research progress of chemokine receptors and chemokine receptor antagonists in resent years are introduced.